N-terminal EF-hand calcium binding protein 2Genealiases: EFCBP2 · stip-2
Q-omics provides the consensus-scored NECAB2 profile across patient tissues and cancer cell-line models. NECAB2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NECAB2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NECAB2 protein abundance shows 25,987 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where NECAB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NECAB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NECAB2 survival associations across molecular data types. NECAB2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NECAB2 RNA expression–survival associations across cancer types. High NECAB2 expression shows unfavorable associations in UVM, ACC, UCEC, LUAD and SKCM, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NECAB2 RNA expression.
This table summarizes NECAB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NECAB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NECAB2 shows lower tumor expression in COAD, THCA and KICH and higher tumor expression in HNSC, LUAD and LUSC. The COAD box plot shows higher NECAB2 RNA expression in normal versus tumor tissue (log2 FC = −0.401, t-test p < 0.001).
This table shows molecular features associated with NECAB2 in patient tissues and cancer cell lines. In patient samples, NECAB2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NECAB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
